Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


France: Trasicor; Germany: Trasicor, Trasitensin, Trepress; Greece: Dialicor, Drisoftaline, Evinrozit, Flecor, Ranidrox, Rixiprol, Secontafil, Tinatrax, Trasicor, Trasitensin, V.K-4, Vrachor, Zetonium; Hungary: Trasicor; Luxembourg: Trasicor; Netherlands: Oxprenolol, Trasicor; Poland: Coretal; Spain: Trasicor, Trasitensin; UK: Trasicor.

North America

USA: Trasicor.


Japan: Astawal, Katehat, Okuspurecol, Oxprenolol, Snering, Trasacor.

Drug combinations

Oxprenolol and Chlortalidone

Oxprenolol, Chlortalidone, and Hydralazine


Oxprenolol Hydrochloride: C~15~H~23~NO~3~ HCl. Mw: 301.81. 2-Propanol, 1-(o-allyloxyphenoxy)-3-isopropylamino-, hydrochloride. CAS-6452-73-9; CAS-6452-71-7 (oxprenolol)(1968).

Pharmacologic Category

Cardiovascular Drugs; β-Adrenergic Blocking Agents. (ATC-Code: C07AA02).

Mechanism of action

A competitive and nonselective antagonist of β-adrenergic receptors. Antagonizes catecholamine-induced tachycardia, thus decreasing cardiac output. Inhibits renin release by kidneys, and inhibits vasomotor centers.

Therapeutic use

Mild or moderate hypertension.

Pregnancy and lactiation implications

Oxprenolol crosses placental barrier and may cause bradycardia in fetus and newborn infants. Enters breast milk (not recommended in nursing women).

Unlabeled use

Nonsevere hypertension in pregnancy (second-line agent).


Hypersensitivity to oxprenolol or any component of the formulation. History of allergic rhinitis, asthma, or allergic bronchospasm. Sinus bradycardia, greater than first degree AV block, sick sinus syndrome, right ventricular failure secondary to pulmonary hypertension, congestive heart failure, cardiogenic shock. Anesthesia with agents that produce myocardial depression. Pregnancy (similar agents). Breast-feeding.

Warnings and precautions

Use caution with history of severe anaphylaxis to allergens (patients taking β-blockers may become more sensitive to repeated challenges). In general, β-blockers should not be used in bronchospastic disease. Consider pre-existing conditions such as sick sinus syndrome before initiating. Use with caution in diabetes mellitus (may potentiate hypoglycemia and/or mask signs and symptoms). Use with caution in compensated heart failure, in severe hepatic insufficiency or inflammatory diseases (risk of increased serum concentrations), in myasthenia gravis, and in peripheral vascular disease (including Raynaud’s). If pheochromocytoma (untreated), adequate α-blockade required prior to use of any β-blocker. Use with caution in history of psychiatric illness (may cause or exacerbate CNS depression). β-Blocker therapy should not be withdrawn abruptly (particularly in coronary artery disease).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart